Evozyne
Latest round
- Series B
Last raised
- Sep 2023
Total raised
- $41M
Investors
- 5
About Evozyne
Based in Illinois, US, and founded in 2020 by co-founders Rama Ranganathan, and Andrew Ferguson, Evozyne, Inc. operates as a biotechnology company, that offers protein-based solutions designed to address challenges and drive sustainable solutions across various sectors.'s core product is the development of novel therapeutics such as IgG Protease, CRISPR, and carbon capture with performance characteristics. These proteins have broad applications in various industries, including therapeutics and sustainability. By leveraging Evozyne's protein engineering technology, these products offer solutions for advancements in areas such as drug development, sustainable energy, and environmental conservation.
Who invested in Evozyne
5 investors across 1 round
See all investors in Evozyne
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Sep 27, 2023
Amount
$41M
Investors
Questions about Evozyne
Who invested in Evozyne?
Evozyne has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Evozyne raised?
Evozyne has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Evozyne last raise money?
Evozyne's most recent round on record is a Series B, in Sep 2023.
What does Evozyne do?
Based in Illinois, US, and founded in 2020 by co-founders Rama Ranganathan, and Andrew Ferguson, Evozyne, Inc.
Where is Evozyne headquartered?
Evozyne is headquartered in Chicago, US.
Which VCs invest in companies like Evozyne?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Evozyne's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Evozyne? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.